Ventyx Biosciences, Inc. (NASDAQ:VTYX – Get Free Report) has received an average recommendation of “Moderate Buy” from the eight research firms that are covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $8.29.
A number of research firms recently weighed in on VTYX. Oppenheimer lowered their price target on Ventyx Biosciences from $12.00 to $10.00 and set an “outperform” rating on the stock in a report on Thursday, June 6th. Wells Fargo & Company lowered their target price on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a report on Monday, August 12th. HC Wainwright reiterated a “neutral” rating and set a $6.00 target price on shares of Ventyx Biosciences in a report on Tuesday, July 30th. Finally, Canaccord Genuity Group lowered their target price on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Monday, August 12th.
Get Our Latest Analysis on VTYX
Institutional Inflows and Outflows
Ventyx Biosciences Price Performance
VTYX opened at $1.96 on Wednesday. The stock has a market cap of $138.51 million, a P/E ratio of -0.60 and a beta of 0.39. The stock’s 50 day simple moving average is $2.41 and its 200 day simple moving average is $4.16. Ventyx Biosciences has a 1-year low of $1.84 and a 1-year high of $38.20.
Ventyx Biosciences (NASDAQ:VTYX – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.12. Research analysts expect that Ventyx Biosciences will post -2.14 EPS for the current fiscal year.
Ventyx Biosciences Company Profile
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
Featured Articles
- Five stocks we like better than Ventyx Biosciences
- Want to Profit on the Downtrend? Downtrends, Explained.
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- What Are the U.K. Market Holidays? How to Invest and Trade
- Lowe’s Stock: Hold Now, Buy it When it Dips
- Options Trading – Understanding Strike Price
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.